

São Paulo, November 05, 2024. RD Saúde (Raia Drogasil S.A. – B3: RADL3) announces its results for the 3rd quarter of 2024 (3Q24). The Company's parent company and consolidated financial statements for the periods ended September 30, 2024 and 2023 have been prepared in accordance with the accounting practices adopted in Brazil, including the rules issued by the Brazilian Securities Commission (CVM), the Brazilian Accounting Standards – General Technical (NBC TG) and the pronouncements issued by the Brazilian Accounting Pronouncements Committee (CPC), and are in conformity with the International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB), and provide all the significant information related solely to the financial statements, which is consistent with the information used by management. The financial statements were prepared in Reais and all growth rates, unless otherwise stated, relate to the same period of the previous year.

IFRS 16: Our financial statements are prepared in accordance with IFRS 16. In order to better represent the economics of the business, the figures in this report are presented under IAS 17, the previous reporting standard. A reconciliation with IFRS 16 can be found in a dedicated chapter within this document.

2023 reclassifications: In the 1Q24, we concluded the reclassification of certain revenues and expenses to ensure their maximum correlation with the Company's activities. These reclassifications refer to the results of 2023 and do not affect the EBITDA, balance sheet or cash flow. More details can be found in the 1Q24 earnings release.

CONSOLIDATED HIGHLIGHTS:

- › **PHARMACIES: 3,139 units in operation (72 openings and 9 closures);**
- › **GROSS REVENUE: R\$ 10.7 billion, a 15.9% increase with 6.7% of mature-store growth;**
- › **MARKET SHARE: 16.0% national share, a 0.3 pp increase;**
- › **DIGITAL: R\$ 1.9 billion, an increase of 40.2% and a retail penetration of 19.0%;**
- › **ADJUSTED EBITDA: R\$ 810.8 million, an increase of 23.2% and a margin of 7.5%;**
- › **EBT: R\$ 437.4 million, an increase of 44.7% and a margin of 4,1%;**
- › **ADJUSTED NET INCOME*: R\$ 336.8 million, a 25.5% increase and a margin of 3.1%;**
- › **CASH FLOW: R\$ 700.6 million positive free cash flow, R\$ 657.6 million total cash generation.**

* Includes the effects of the taxation of investment subsidies, in accordance with Law No. 14,789/2023.

RADL3

R\$ 25.18/share

Closing: November 04, 2024

MARKET CAP

R\$ 43.3 billion

NUMBER OF SHARES

1,718,007,200

IR TEAM:


Flávio Correia
André Stolfi
Victor Torres
Felipe Correa

ir.rdsaude.com.br

ri@rdsaude.com.br

Summary (R\$ thousands)	3Q23	4Q23	1Q24	2Q24	3Q24
# of pharmacies	2,868	2,953	3,010	3,076	3,139
Organic openings	64	87	62	70	72
Closures	(3)	(2)	(5)	(4)	(9)
Headcount (EoP)	57,295	57,691	57,708	59,341	62,402
Pharmacist count (EoP)	11,726	12,047	12,306	12,429	12,689
# of tickets (thousands)	91,261	94,401	95,846	102,141	102,620
# of active customers (MM)	46.4	47.6	48.2	48.8	49.1
Gross revenue	9,274,782	9,538,836	9,767,156	10,402,635	10,749,830
Growth (YoY)	+16.2%	+14.3%	+15.3%	+15.4%	+15.9%
Gross profit	2,578,822	2,670,232	2,659,264	2,931,999	2,970,685
% of gross revenue	27.8%	28.0%	27.2%	28.2%	27.6%
Adjusted EBITDA	658,097	614,544	679,850	824,396	810,753
% of gross revenue	7.1%	6.4%	7.0%	7.9%	7.5%
Adjusted net income	268,443	283,315	213,700	356,613	336,819
% of gross revenue	2.9%	3.0%	2.2%	3.4%	3.1%
Net income	296,570	284,651	213,014	348,425	362,117
% of gross revenues	3.2%	3.0%	2.2%	3.3%	3.4%
Free cash flow	336,224	150,930	(118,057)	(303,369)	700,579


STORE DEVELOPMENT



We ended the 3Q24 with a total of 3,139 pharmacies, having opened 72 new units in the quarter and closed 9. In the last 12 months, we have opened a total of 291 pharmacies.


Of the 9 closures in the quarter, only 2 were pharmacies in the maturation process. In the last twelve months, the closure of units still undergoing maturation was approximately 2% of LTM openings, a result of the high assertiveness of our expansion process. The remaining 15 LTM closures were of mature units with an average of 11 years of operation and were the result of the optimization of our portfolio, transferring revenues to our remaining locations in the neighborhood while eliminating a full fixed-cost base and releasing assets to be more efficiently redeployed, thus increasing both the Company's EBITDA and ROIC.

At the end of the quarter, a total of 25.9% of our pharmacies were still maturing and had not yet reached their full potential both in terms of revenue and profitability.




Our expansion continues to diversify our pharmacy network, both geographically and demographically. We have extended our presence to 610 cities, 48 more than in the 3Q23, a unique capillarity in Brazilian retail. Of the 291 gross openings in the last 12 months, 68% occurred outside the state of São Paulo, our native market. Additionally, out of the 319 Brazilian cities with over 100 thousand inhabitants, we already have, or are in the process of opening, pharmacies in 313 of them. Lastly, 83% of our openings in the last 12 months have popular or hybrid formats, which already comprise 60% of our total store portfolio.

Geographic presence



Market share

Quarterly retail share at Factory Prices (sell-out + sell-in)



Source: IQVIA. Southeast excludes SP.

We are present in all Brazilian states and operate 14 distribution centers that support our more than 3.1 thousand pharmacies. Our logistics network allows us to replenish 92% of our stores on a daily basis, improving service levels, optimizing working capital and reinforcing our operational efficiency, thus constituting an important competitive advantage.

Our national share was of 16.0%, an annual increase of 0.3 pp. We recorded a market share of 28.0% in São Paulo (+0.6 pp), of 11.7% in the Southeast (+0.7 pp), of 19.0% in the Midwest (-0.3 pp), of 10.8% in the South (+0.2 pp), of 11.0% in the Northeast (+0.1 pp), and of 9.2% in the North (+0.3 pp).


We highlight that IQVIA recorded an atypically higher growth in the indirectly informed sales (sell-in) in the Midwest. This indirect data, typically sales of distributors to small pharmacies, may result in imprecise estimates of market performance as they do not represent the final sales to consumers. When solely analyzing the directly informed sales data from chains to the end consumer (sell-out), we recorded a stable market share in the region.

DIGITAL, HEALTH AND CUSTOMER ENGAGEMENT

One of our key drivers for value creation is the increase of the Lifetime Value of our customers, built upon a strategy of creating relevant bonds and greater engagement. We ended the 3Q24 with 49.1 million active customers and 102.6 million purchases in the quarter.


Digital sales and penetration

R\$ millions, % of retail gross revenue



Digital channel mix


% of digital sales



* Call center represents < 1% of the mix.

Delivery mix

% of digital sales



We continue to advance in our digital strategy, strengthening this important bond with the customer. We reached R\$ 1,859.2 million in revenues through our digital channels, a growth of 40.2% when compared to the 3Q23. These channels, which would be among the top 5 pharmacies in the country if considered isolated, reached a retail penetration of 19.0%, an increase of 3.5 pp in the last 12 months.

We highlight the evolution of our app penetration within digital sales, which advanced from 65% to 75% in the last 12 months, ensuring a mobile customer experience designed by RD Saúde for a complete and omnichannel integral health journey. Another highlight comes from deliveries in up to 60 minutes, which already represent 25% of digital sales. When combined with Click & Collect and deliveries by third-party apps, we cover 94% of digital sales delivered or collected within 60 minutes. This unique capability at a national scale is only possible with the capillarity of our pharmacy footprint which covers 94% of the Brazilian A class population within a 1.5 km radius.


In the quarter, we recorded 165.7 million visits to our digital channels and our digitalized frequent customers spent 23% more than non-digitalized frequent customers. Additionally, we continue to advance in the development of our Marketplace to improve the customer experience within our digital channels through an expanded assortment of 268 thousand SKUs in health and wellness provided by 1,155 different sellers.

Another important bond with our customers is Stix, the leading coalition of loyalty programs in Brazilian retail, which includes partners such as Drogasil, Raia, Pão de Açúcar, Extra Mercado, Shell, Livelu, C&A and Sodimac. Stix allows its 8.0 million active customers to earn and redeem points within the expanded ecosystem of over 8 thousand stores. Among these customers, 4.2 million used the program at more than one partner, underscoring the impact of the coalition.


Lastly, we continue to reinforce the role of our pharmacies in the integral health journey of our customers, positioning them as health hubs within the communities they serve and strengthening customer bonds by providing health services. We already count 2.3 thousand health hubs offering an expanded portfolio of services, as well as 345 units licensed for vaccines. In the 3Q24, these pharmacies performed 1.5 million pharmaceutical services, including CATs (clinical analysis tests), vaccinations and other services.

GROSS REVENUES

Consolidated gross revenues




Retail sales mix




We ended the 3Q24 with a record gross revenue of R\$ 10,749.8 million, a growth of 15.9%. Our retail sales grew 14.5%, with 4Bio contributing with 1.4 pp. Additionally, we recorded a positive calendar effect of 0.1 pp.

The highlight of the quarter were generics with a growth of 17.0%, while branded Rx grew 15.9% and OTC 15.3%. Lastly, HPC grew 9.9%, pressured by the strong comp base of the 3Q23, when the category grew 9.5 pp above the rest of retail.


Consolidated revenue growth



Same-Store sales growth – Retail



Mature-Store sales growth – Retail




■ CMED price adjustment ■ Real growth

We recorded in the 3Q24 a same-store sales growth of 9.1%. We highlight the fact that our stores have a 3-year maturation curve and, with 25.9% of pharmacies still in this maturation process, same-store sales growth includes the effects of this initial ramp-up.

Considering mature stores, we recorded a growth of 6.7%, a 2.2 pp real growth above the CMED price readjustment of 4.5%.


↔ **GROSS PROFIT**



Gross profit totaled R\$ 2,970.7 million in the 3Q24, with a gross margin of 27.6%, a contraction of 0.2 pp when compared to the 3Q23.


We recorded a margin pressure of 0.4 pp due to the 4Bio mix effect, as a consequence of it growing above retail. Additionally, we recorded pressures of 0.1 pp from the non-cash NPV effect, mainly due to the lower SELIC interest rate, and of 0.1 pp from the additional PIS/COFINS taxes on investment subsidies since the 1Q24, as established by Law No. 14,789/2023. These pressures were partially offset by 0.2 pp from commercial gains and by 0.2 pp from a non-recurring gain related to retroactive ICMS reimbursements referring to the 1H24.

↔ **SELLING EXPENSES**




Selling expenses totaled R\$ 1,836.8 million in the 3Q24, equivalent to 17.1% of gross revenue and a 0.3 pp dilution compared to the 3Q23. We recorded pressures of 0.1 pp from marketing expenses, of 0.1 pp from transportation expenses and of 0.1 pp in software licenses, more than offset by a dilution of 0.2 pp in rentals and a momentary dilution of 0.4 pp in personnel expenses.

↔ **CONTRIBUTION MARGIN**



The contribution margin in the 3Q24 was R\$ 1,133.9 million, an increase of 17.5% over the 3Q23. This represents 10.5% of gross revenue, a 0.1 pp expansion vs. the 3Q23, driven by the 0.3 pp dilution in selling expenses more than offsetting the 0.2 pp gross margin contraction.

↔ **GENERAL & ADMINISTRATIVE EXPENSES**




General and administrative expenses totaled R\$ 323.1 million in the 3Q24, equivalent to 3.0% of gross revenue. This represents a dilution of 0.3 pp compared to the 3Q23, reflecting the robust sales performance in the quarter combined with the Company's efforts to manage these expenses.

↔ **EBITDA**

We achieved an adjusted EBITDA of R\$ 810.8 million in the 3Q24, an increase of 23.2% compared to the 3Q23. The EBITDA margin was 7.5% of gross revenue, a 0.4 pp expansion compared to the 3Q23, driven by a 0.3 pp dilution in selling expenses, an additional 0.3 pp dilution in general and administrative expenses, more than offsetting the 0.2 pp gross margin contraction.

Adjusted EBITDA

R\$ millions, % of gross revenue



EBITDA RECONCILIATION AND NON-RECURRING RESULTS


EBITDA Reconciliation (R\$ millions)	3Q24	3Q23
Net income	362.1	296.6
Income tax	113.6	48.3
Equity Equivalence	0.2	1.9
Financial Result	141.6	149.7
EBIT	617.5	496.4
Depreciation and amortization	231.5	204.3
EBITDA	849.1	700.7
Tax effects and other non-recurring from previous years	(117.8)	(49.5)
Social investments and donations	3.9	2.1
Asset write-offs	2.0	1.1
Other non-recurring/non-operating effects	73.7	3.7
Non-recurring/non-operating expenses	(38.3)	(42.6)
Adjusted EBITDA	810.8	658.1

In the 3Q24, we recorded R\$ 38.3 million in net non-recurring revenues. This includes R\$ 117.8 million in revenues from tax effects of previous years, of which R\$ 89.9 million were of ICMS reimbursements and R\$ 30.2 million were mostly PIS/COFINS tax credits. We also recorded non-recurring expenses of R\$ 3.9 million in social investments and donations, R\$ 2.0 million in asset write-offs and R\$ 73.7 million in other non-recurring expenses, including R\$ 70.0 million from the revision of the non-cash NPV effects of previous years.

DEPRECIATION, NET FINANCIAL EXPENSES AND EARNINGS BEFORE TAXES


Depreciation

R\$ millions, % of gross revenue




Net financial expenses

R\$ millions, % of gross revenue



Earnings before taxes

R\$ millions, % of gross revenue



Depreciation expenses amounted to R\$ 231.5 million in the 3Q24, equivalent to 2.2% of gross revenue, stable when compared to the 3Q23.


Net financial expenses represented 1.3% of gross revenue in the 3Q24, a reduction of 0.3 pp compared to the 3Q23. Of the R\$ 141.6 million, R\$ 92.2 million refer to the actual interests accrued on financial liabilities, equivalent to 0.9% of gross revenue, a 0.1 pp decrease when compared to the 3Q23 mostly due to the SELIC interest rate. We also recorded R\$ 47.1 million in non-cash NPV adjustments, equivalent to 0.4% of gross revenue with a 0.2 pp reduction vs. the 3Q23, and R\$ 2.3 million in interest related to invested companies.

We recorded an EBT of R\$ 437.4 million in the 3Q24, equivalent to 4.1% of gross revenue. This equates to an increase of 44.7% vs. the 3Q23 and a margin expansion of 0.8 pp.

INCOME TAXES AND NET INCOME

Income tax and effective tax rate


R\$ millions, % of earnings before taxes



* Effective tax rate

Adjusted net income**

R\$ millions, % of gross revenue



** Includes the effects of the taxation of investment subsidies, in accordance with Law No. 14,789/2023.


We recorded an income tax of R\$ 100,6 million in the 3Q24. This was equal to 0.9% of gross revenue in the quarter, a 0.5 pp increase when compared to the 3Q23. The effective tax rate was 23.0% of EBT, an increase of 11.8 pp. Our YTD income tax increased by 151.3% when compared to the same period of the previous year, driven by the start of taxation on investment subsidies, in accordance to Law No. 14,789/2023.

This resulted in an adjusted net income of R\$ 336.8 million in the 3Q24, a 25.5% increase compared to the 3Q23. The net margin was 3.1% of gross revenue, a 0.2 pp contraction compared to the same period of the previous year, despite the increased taxation.

CASH CYCLE

Cash cycle*

COGS days, Gross revenue days



* Adjusted for discounted receivables and advanced payments to suppliers.

The cash cycle in the 3Q24 was of 59.6 days, a reduction of 3.3 days vs. same period of the previous year and a reduction of 7.3 days vs. the 2Q24.

↔ CASH FLOW

Cash flow (R\$ millions)	3Q24	3Q23
Adjusted EBIT	579.2	453.8
NPV adjustment	(47.1)	(48.8)
Non-recurring expenses	38.3	42.6
Income tax (34%)	(194.0)	(152.2)
Depreciation	232.8	204.5
Others	(76.2)	1.8
Resources from operations	533.1	501.7
Cash cycle*	376.4	105.2
Other assets (liabilities)**	152.8	68.9
Operating cash flow	1,062.3	675.7
Investments	(361.7)	(339.5)
Free cash flow	700.6	336.2
M&A and other investments	(7.4)	(10.8)
Interest on equity and dividends	(1.1)	(0.3)
Income tax paid over interest on equity	(10.8)	(27.9)
Net financial expenses***	(94.5)	(98.7)
Tax benefit (fin. exp., IoE, dividends)	70.9	64.5
Total Cash Flow	657.6	263.1

*Includes adjustments to discounted receivables.

**Includes NPV adjustments.

***Excludes NPV adjustments.

In the 3Q24, we recorded a positive free cash flow of R\$ 700.6 million, with a total cash generation of R\$ 657.6 million. Resources from operations totaled R\$ 533.1 million, equivalent to 5.0% of gross revenue. We recorded a working capital of R\$ 529.2 million, resulting in an operating cash flow of R\$ 1,062.3 million, more than financing the CAPEX of R\$ 361.7 million.

Of the R\$ 361.7 million invested in the quarter, R\$ 140.1 million were used for the opening of new pharmacies, R\$ 61.6 million for the renovation of existing units, R\$ 111.4 million for IT, R\$ 37.2 million in logistics and R\$ 11.5 million in other projects. Additionally, we allocated R\$ 7.4 million into investments in subsidiaries.

In the 3Q24, net financial expenses resulted in payments of R\$ 94.5 million. These were partially offset by R\$ 70.9 million in tax benefits related to net financial expenses and to interest on equity. Lastly, we provisioned R\$ 114.1 million in interest on equity, compared to the R\$ 91.1 million provisioned in the 3Q23.


↔ INDEBTEDNESS

Net Debt (R\$ millions)	3Q23	4Q23	1Q24	2Q24	3Q24
Short-term Debt	581.0	604.6	311.9	415.4	619.0
Long-term Debt	2,523.5	2,526.1	2,528.0	3,003.3	2,655.1
Total Gross Debt	3,104.5	3,130.7	2,839.9	3,418.7	3,274.2
(-) Cash and Equivalents	593.6	412.3	412.6	369.7	410.5
Net Debt	2,510.9	2,718.4	2,427.3	3,049.1	2,863.7
Discounted Receivables	47.8	-	449.7	523.5	32.2
Advances to suppliers	(12.6)	(49.6)	(60.1)	(56.0)	(37.2)
Put/Call options of investments (estimated)	98.2	98.2	129.3	12.9	13.2
Adjusted Net Debt	2,644.3	2,766.9	2,946.3	3,529.5	2,871.9
Adjusted Net Debt / EBITDA	1.0x	1.1x	1.1x	1.3x	1.0x

We ended the 3Q24 with an adjusted net debt of R\$ 2,871.9 million, corresponding to a leverage of 1.0x the adjusted EBITDA of the last 12 months and a sequential reduction of 0.3x vs. the 2T24. Our adjusted net debt considers R\$ 32.2 million in discounted receivables, R\$ 37.2 million in advanced payments to suppliers, and R\$ 13.2 million in liabilities related to the put option granted and/or call option obtained for the acquisition of the remaining equity of invested companies.

At the end of the quarter, our gross debt totaled R\$ 3,274.2 million, of which 97% corresponds to debentures and Certificates of Real Estate Receivables (CRIs), with the remaining 3% corresponding to other credit lines. Of the total debt, 81% is due in the long-term and 19% in the short-term. We ended the quarter with a total cash and equivalents position of R\$ 410.5 million.

↔ **TOTAL SHAREHOLDER RETURNS**



Our share price decreased by 0.7% in the 3Q24, a difference of 7.1 pp vs. the 6.4% appreciation of the IBOVESPA. During the period, the average daily financial volume (ADTV) was of R\$ 173 million.

Since the IPO of Drogasil in 2007, we achieved a cumulative share appreciation of 2,176% compared to an appreciation of only 142% for the IBOVESPA. Including the payment of interest on equity and dividends, we generated an average annual total return to shareholders of 20.6%.

Considering the IPO of Raia in 2010, the cumulative return amounted to 810% compared to an increase of only 94% for the IBOVESPA. Considering the payment of interest on equity and dividends, this resulted in an average annual total return to shareholders of 18.0%.

↔ **RD SAÚDE DAY 2024**

RDsaúde Day

Save the date!



Monday, **December 2nd**, 2024

Agenda

2 pm – Welcome Coffee

2:30 pm to 6 pm – Event time

Address: RD Saúde Campus
Av. Corifeu de Azevedo Marques, 3097
Butantã – São Paulo - SP

We recommend the use of transportation apps.
Limited parking will be available.

IFRS-16

Since 2019, our financial statements have been prepared in accordance with IFRS 16. In order to preserve historic comparability, the figures in this report are presented under IAS 17, the previous reporting standard, which we believe best represents the economic performance of our operations.

Financial statements in both IAS 17 and IFRS 16 are also available at our website ir.rdsaude.com.br under Results Spreadsheet.

Income Statement (R\$ millions)	3Q24		Change
	IAS 17	IFRS 16	Δ 3Q24
Gross Revenue	10,749.8	10,749.8	0.0
Gross Profit	2,970.7	2,970.9	0.2
Gross Margin	27.6%	27.6%	0.0 pp
Selling Expenses	(1,836.8)	(1,545.9)	290.9
G&A	(323.1)	(321.2)	1.9
Total Expenses	(2,159.9)	(1,867.1)	292.8
as % of Gross Revenue	20.1%	17.4%	(2.7 pp)
Adjusted EBITDA	810.8	1,103.8	293.1
as % of Gross Revenue	7.5%	10.3%	2.8 pp
Non-Recurring Expenses / Revenues	38.3	40.2	1.9
Depreciation and Amortization	(231.5)	(464.8)	(233.3)
Financial Results	(141.6)	(238.1)	(96.5)
Equity Equivalence	(0.2)	(0.2)	(0.0)
Income Tax	(113.6)	(101.8)	11.9
Net Income	362.1	339.1	(23.0)
as % of Gross Revenue	3.4%	3.2%	(0.2 pp)

Balance Sheet (R\$ millions)	3Q24		Change
	IAS 17	IFRS 16	Δ 3Q24
Assets	18,091.8	21,956.0	3,864.2
Current Assets	12,890.4	12,890.4	0.0
Non-Current Assets	5,201.4	9,065.6	3,864.2
Income Tax and Social Charges deferred	79.5	194.4	114.9
Other Credits	10.1	9.7	(0.4)
Right of use	0.0	3,749.8	3,749.8
Liabilities and Shareholder's Equity	18,091.8	21,956.0	3,864.2
Current Liabilities	8,360.4	9,298.2	937.9
Financial Leases	0.0	947.1	947.1
Other Accounts Payable	391.2	382.0	(9.2)
Non-Current Liabilities	3,061.2	6,341.7	3,280.4
Financial Leases	0.0	3,347.7	3,347.7
Income Tax and Social Charges Deferred	67.3	0.0	(67.3)
Shareholder's Equity	6,670.2	6,316.1	(354.1)
Income Reserves	1,871.2	1,577.4	(293.8)
Accrued Income	542.9	482.8	(60.1)
Non Controller Interest	13.6	13.5	(0.1)

Cash Flow (R\$ millions)	3Q24		Change
	IAS 17	IFRS 16	Δ 3Q24
Adjusted EBIT	579.2	639.0	59.8
Non-Recurring Expenses	38.3	40.2	1.9
Income Tax (34%)	(194.0)	(214.9)	(21.0)
Depreciation	232.8	464.8	232.0
Rental Expenses	0.0	(294.7)	(294.7)
Others	(76.2)	(54.2)	22.0
Resources from Operations	533.1	533.1	0.0
Operating Cash Flow	1,062.3	1,062.3	0.0
Investments	(361.7)	(361.7)	0.0
Free Cash Flow	700.6	700.6	0.0
Total Cash Flow	657.6	657.6	0.0

*Includes adjustments to discounted receivables.

**Includes NPV adjustments

***Excludes NPV adjustments

↔ RESULTS CONFERENCE CALLS

**November 06th 2024, 10:00 AM (BRT),
with simultaneous translation to English.**

Access Link

<https://www.resultadosrdsaude.com.br/>

For more information, please contact our Investor Relations department: ri@rdsaude.com.br

Consolidated Adjusted Income Statement	3Q23	3Q24
(R\$ thousands)	Reclassified	
Gross Revenue	9,274,782	10,749,830
Taxes, Discounts and Returns	(610,296)	(760,708)
Net Revenue	8,664,486	9,989,122
Cost of Goods Sold	(6,085,664)	(7,018,436)
Gross Profit	2,578,822	2,970,685
Operational (Expenses) Revenues		
Sales	(1,614,133)	(1,836,801)
General and Administrative	(306,592)	(323,131)
Operational Expenses	(1,920,725)	(2,159,932)
EBITDA	658,097	810,753
Depreciation and Amortization	(204,298)	(231,549)
Operational Earnings before Financial Results	453,799	579,204
Financial Expenses	(244,874)	(238,926)
Financial Revenue	95,160	97,337
Financial Expenses/Revenue	(149,715)	(141,589)
Equity Equivalence	(1,854)	(209)
Earnings before Income Tax and Social Charges	302,230	437,405
Income Tax and Social Charges	(33,786)	(100,586)
Net Income	268,443	336,819

Consolidated Income Statement	3Q23	3Q24
(R\$ thousands)	Reclassified	
Gross Revenue	9,274,782	10,749,830
Taxes, Discounts and Returns	(610,296)	(760,708)
Net Revenue	8,664,486	9,989,122
Cost of Goods Sold	(6,085,664)	(7,018,436)
Gross Profit	2,578,822	2,970,685
Operational (Expenses) Revenues		
Sales	(1,614,133)	(1,836,801)
General and Administrative	(306,592)	(323,131)
Other Operational Expenses, Net	42,616	38,329
Operational Expenses	(1,878,109)	(2,121,603)
EBITDA	700,713	849,082
Depreciation and Amortization	(204,298)	(231,549)
Operational Earnings before Financial Results	496,415	617,533
Financial Expenses	(244,874)	(238,926)
Financial Revenue	95,160	97,337
Financial Expenses/Revenue	(149,715)	(141,589)
Equity Equivalence	(1,854)	(209)
Earnings before Income Tax and Social Charges	344,846	475,735
Income Tax and Social Charges	(48,276)	(113,618)
Net Income	296,570	362,117

Assets (R\$ thousands)	3Q23	3Q24
Cash and Cash Equivalents	593,587	410,510
Financial Investments	25,938	-
Accounts Receivable	2,904,270	3,362,713
Inventories	6,925,863	8,132,532
Taxes Receivable	417,496	377,907
Other Accounts Receivable	362,581	486,600
Anticipated Expenses	91,062	117,745
Deposit in Court	-	2,378
Current Assets	11,320,796	12,890,386
Deposit in Court	131,429	247,105
Taxes Receivable	118,949	300,577
Income Tax and Social Charges deferred	34,905	79,493
Other Credits	15,994	10,083
Investments	5,927	9,558
Property, Plant and Equipment	2,364,103	2,563,820
Intangible	1,876,388	1,990,746
Non-Current Assets	4,547,697	5,201,382
TOTAL ASSETS	15,868,493	18,091,768
Liabilities and Shareholder's Equity (R\$ thousands)	3Q23	3Q24
Suppliers	4,642,771	5,712,823
Loans and Financing	581,004	619,037
Salaries and Social Charges Payable	735,010	816,547
Taxes Payable	289,771	414,068
Dividend and Interest on Equity	238,729	336,980
Provision for Lawsuits	53,569	69,726
Other Accounts Payable	316,708	391,189
Current Liabilities	6,857,562	8,360,369
Loans and Financing	2,523,461	2,655,148
Provision for Lawsuits	60,653	235,310
Income Tax and Social Charges deferred	114,853	67,266
Other Accounts Payable	228,136	103,506
Non-Current Liabilities	2,927,103	3,061,230
Common Stock	4,000,000	4,000,000
Capital Reserves	136,617	168,673
Revaluation Reserve	11,242	11,116
Income Reserves	1,281,229	1,871,215
Accrued Income	578,246	542,904
Equity Adjustments	3,261	62,688
Non Controller Interest	73,233	13,573
Shareholder's Equity	6,083,828	6,670,169
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	15,868,493	18,091,768

Cash Flow (R\$ thousands)	3Q23	3Q24
Earnings before Income Tax and Social Charges	307,450	362,155
Adjustments		
Depreciation and Amortization	204,475	232,772
Compensation plan with restricted shares, net	10,871	11,049
Interest over additional stock option	1,428	341
PP&E and Intangible Assets residual value	3,359	4,946
Provisioned Lawsuits	20,333	4,767
Provisioned Inventory Loss	255	13,395
Provision for Doubtful Accounts	4,901	6,375
Provisioned Store Closures	(783)	(3,110)
Interest Expenses	88,264	93,513
Debt Issuance Costs Amortization	1,360	5,233
Equity Equivalence Result	2,100	213
	644,013	731,649
Assets and Liabilities variation		
Clients and Other Accounts Receivable	(842,250)	(458,958)
Inventories	(299,031)	(452,369)
Other Short Term Assets	(38,272)	45,307
Long Term Assets	(16,145)	(1,814)
Suppliers	529,283	815,106
Salaries and Social Charges	108,625	100,000
Taxes Payable	(61,799)	(114,778)
Other Liabilities	44,132	124,428
Rents Payable	2,517	2,175
Cash from Operations	71,073	790,746
Interest Paid	(103,049)	(100,486)
Income Tax and Social Charges Paid	(68,125)	(115,274)
Paid lawsuits	(15,164)	(24,261)
Net Cash from (invested) Operational Activities	(115,265)	550,725
Investment Activities Cash Flow		
PP&E and Intangible Acquisitions	(349,065)	(369,187)
Cash from incorporated company	(1,179)	-
Net Cash from Investment Activities	(350,244)	(369,187)
Financing Activities Cash Flow		
Funding	833,796	423
Payments	(119,706)	(140,000)
Interest on Equity and Dividends Paid	(303)	(1,111)
Net Cash from Funding Activities	713,787	(140,688)
Cash and Cash Equivalents in the beginning of the period	345,309	369,660
Cash and Cash Equivalents net increase	248,278	40,850
Cash and Cash Equivalents in the end of the period	593,587	410,510